The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients

Journal of Clinical Psychopharmacology

Volumn 34, Issue 2, 2014, Pages 256-260

  Van Der Weide, Karen ^a   Van Der Weide, Jan ^a,b  

^a ST JANSDAL HOSPITAL   (Netherlands)

^b Mental Healthcare Service GGz Centraal   (Netherlands)

Author keywords

CYP3A4*22; Cytochrome P450 3A4; Pharmacogenetics; Quetiapine; Single nucleotide polymorphism

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 3A4; DILTIAZEM; DNA; KETOCONAZOLE; PHENYTOIN; PREDNISOLONE; QUETIAPINE; VALPROIC ACID; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CYTOCHROME P450 3A4 GENE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PSYCHOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT; ADOLESCENT; BLOOD; CASE CONTROL STUDY; GENETICS; HETEROZYGOTE; MENTAL DISEASE; NETHERLANDS; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP3A; DIBENZOTHIAZEPINES; FEMALE; HETEROZYGOTE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84896394539     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000070     Document Type: Article

References (39)

1. Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry. 2000;61(suppl 2): 10-12.
2. Ozdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000;10: 373-388.
3. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002;3: 561-597.
4. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54: 1271-1294.
5. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270: 414-423.
6. Westlind-Johnsson A, Malmebo S, Johansson A, et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos. 2003;31: 755-761.
7. Veronese ML, Gillen LP, Burke JP, et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol. 2003;43: 831-839.
8. Schirmer M, Rosenberger A, Klein K, et al. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics. 2007;8: 443-453.
9. George J, Byth K, Farrell GC. Influence of clinicopathological variables on CYP protein expression in human liver. J Gastroenterol Hepatol. 1996;11: 33-39.
10. Grimm SW, Richtand NM, Winter HR, et al. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61: 58-69.
11. Pollack TM, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy. 2009;29: 1386-1391.
12. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104: 173-192.
13. Swen JJ, Wilting I, de Goede AL, et al. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther. 2008;83: 781-787.
14. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byteVan update of guidelines. Clin Pharmacol Ther. 2011;89: 662-673.
15. McDonagh EM, Whirl-Carrillo M, Garten Y, et al. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med. 2011;5: 795-806.
16. Ingelman M, Daly AK, Nebert DW, et al. The human cytochrome P450 (CYP) allele nomenclature database [Homepage Committee HCPAN]. March 5, 2013. Available at: http://www.cypalleles.ki.se. Accessed January 8, 2013.
17. van Schaik RHN, van der Werf M, van der Heiden IP, et al. CYP3A4, CYP3A5 and MDR-1 variant alleles in the Dutch Caucasian population. Clin Pharmacol Ther. 2003;192: 23-32.
18. Lamba JK, Lin YS, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 2002;12: 121-132.
19. Garcia-Martin E, Martinez C, Pizarro RM, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther. 2002;71: 196-204.
20. Wang D, Guo Y, Wrighton SA, et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011;11: 274-286.
21. Elens L, Becker ML, Haufroid V, et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics. 2011;21: 861-866.
22. Elens L, Bouamar R, Hesselink DA, et al. The new CYP3A4 intron 6 C9T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics. 2012;22: 373-380.
23. Elens L, van Schaik RH, Panin N, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics. 2011;12: 1383-1396.
24. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011;57: 1574-1583.
25. Stockmann C, Fassl B, Gaedigk R, et al. Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control. J Pediatr. 2013;162: 1222-1227.
26. Hasselstrom J, Linnet K. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. Drug Metabol Drug Interact. 2006;21: 187-211.
27. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40: 509-522.
28. Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008;33: 2303-2312.
29. Nikisch G, Baumann P, Oneda B, et al. Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. J Psychopharmacol. 2011;25: 896-907.
30. Winter HR, Earley WR, Hamer-Maansson JE, et al. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol. 2008;18: 81-98.
31. Flockhart DA. P450 drug interaction table [Division of Clinical Pharmacology, Indiana University]. January 25, 2012. Available at: http://medicine.iupui.edu/clinpharm/ddis/table.aspx. Accessed May 21, 2013.
32. Aichhorn W, Marksteiner J, Walch T, et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol. 2006;21: 81-85.
33. Kootstra-Ros JE, van Weelden MJ, Hinrichs JW, et al. Therapeutic drug monitoring of antidepressants and cytochrome p450 genotyping in general practice. J Clin Pharmacol. 2006;46: 1320-1327.
34. Hasselstrom J, Linnet K. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. Ther Drug Monit. 2004;26: 486-491.
35. Dev V, Raniwalla J. Quetiapine: a reviewof its safety in the management of schizophrenia. Drug Saf. 2000;23: 295-307.
36. Williams JA, Cook J, Hurst SI. A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos 2003;31: 1526-1530.
37. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27: 383-391.
38. Bakken GV, Rudberg I, Christensen H, et al. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009;37: 254-258.
39. van der Weide J, Hinrichs JW. The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. Clin Biochem Rev. 2006;27: 17-25.